within Pharmacolibrary.Drugs.ATC.A;

model A10XA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10XA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tolrestat is an aldose reductase inhibitor previously investigated for the treatment of diabetic complications, particularly diabetic neuropathy and retinopathy. It acts by inhibiting the enzyme aldose reductase, which is involved in the polyol pathway that becomes overactive in chronic hyperglycemia. Tolrestat is not currently approved due to safety concerns, including reports of fatal liver toxicity.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adult subjects based on secondary literature and typical values for similar drugs; no direct clinical pharmacokinetic study for tolrestat identified.</p><h4>References</h4><ol><li><p>Hicks, DR, et al., &amp; Dvornik, D (1984). Tolrestat kinetics. <i>Clinical pharmacology and therapeutics</i> 36(4) 493–499. DOI:<a href=\"https://doi.org/10.1038/clpt.1984.209\">10.1038/clpt.1984.209</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6478735/\">https://pubmed.ncbi.nlm.nih.gov/6478735</a></p></li><li><p>Dvornik, D, et al., &amp; Kraml, M (1994). Tolrestat pharmacokinetics in rat peripheral nerve. <i>Journal of diabetes and its complications</i> 8(1) 18–26. DOI:<a href=\"https://doi.org/10.1016/1056-8727(94)90006-x\">10.1016/1056-8727(94)90006-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8167382/\">https://pubmed.ncbi.nlm.nih.gov/8167382</a></p></li><li><p>Fruncillo, R, et al., &amp; Chiang, S (1996). Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes. <i>Clinical pharmacology and therapeutics</i> 59(6) 603–612. DOI:<a href=\"https://doi.org/10.1016/S0009-9236(96)90000-4\">10.1016/S0009-9236(96)90000-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8681485/\">https://pubmed.ncbi.nlm.nih.gov/8681485</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10XA01;
